Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Necrosis01:16

Necrosis

4.7K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.7K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.2K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.2K
Hematopoiesis01:21

Hematopoiesis

5.5K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.5K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

4.4K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
4.4K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Multi-omics profiles of sex hormone-binding globulin are associated with subclinical atherosclerosis in men with HIV.

Genome medicine·2026
Same author

Colocalization of eQTLs With Type 2 Diabetes and Glycemic Traits Using Whole-Genome Sequences in Diverse Populations From the NHLBI Trans-Omics in Precision Medicine (TOPMed) Program.

Diabetes·2026
Same author

Circulating metabolites associated with protection against Mycobacterium tuberculosis infection and inhibition of mycobacterial growth.

Communications biology·2026
Same author

Sex-specific omics scores of sex hormones and associations with metabolic and sleep disorders.

medRxiv : the preprint server for health sciences·2026
Same author

Multi-omics analysis of the gut microbiome and carotid artery atherosclerosis in men with and without HIV.

EBioMedicine·2026
Same author

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

関連する実験動画

Updated: Aug 9, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.1K

人体造血幹細胞のフェロプトーシスに対する脆弱性

Jiawei Zhao1, Yuemeng Jia2, Dilnar Mahmut1

  • 1Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Cell
|February 21, 2023
PubMed
まとめ

血液形成幹細胞 (HSC) は,タンパク質合成の調節に関連した細胞死の一種であるフェロプトーシスに対する脆弱性を表しています. フェロプトーシスを阻害すると,HSCが救われ,骨髄不全とHSCの維持における重要なメカニズムが明らかになる.

キーワード:
フェロプトーシス遺伝的障害ヘマトポエシス造血幹細胞リボソームプロファイリング翻訳

さらに関連する動画

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

993
Assessment of Cellular Bioenergetics in Mouse Hematopoietic Stem and Primitive Progenitor Cells using the Extracellular Flux Analyzer
10:17

Assessment of Cellular Bioenergetics in Mouse Hematopoietic Stem and Primitive Progenitor Cells using the Extracellular Flux Analyzer

Published on: September 24, 2021

2.7K

関連する実験動画

Last Updated: Aug 9, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.1K
Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

993
Assessment of Cellular Bioenergetics in Mouse Hematopoietic Stem and Primitive Progenitor Cells using the Extracellular Flux Analyzer
10:17

Assessment of Cellular Bioenergetics in Mouse Hematopoietic Stem and Primitive Progenitor Cells using the Extracellular Flux Analyzer

Published on: September 24, 2021

2.7K

科学分野:

  • 血液学
  • 細胞生物学
  • 生物化学

背景:

  • 血液形成幹細胞 (HSC) は,タンパク質の合成を調節するなど,生涯にわたる血液生成に特異的な適応を備えている.
  • これらの適応から生じる特定の脆弱性は,まだ完全に理解されていません.
  • MYSM1欠乏症は,HSCが劣化した骨髄不全症候群を引き起こします.

研究 の 目的:

  • HSCにおけるタンパク質合成の調節とフェロプトーシスの関連性を調査する.
  • フェロプトーシスがHSCの脆弱性であり,MYSM1欠乏症の骨髄不全におけるその役割を決定する.
  • HSCの喪失に対する治療戦略を探求する.

主な方法:

  • MYSM1欠乏したモデルからHSCを研究した.
  • HSCにおけるタンパク質合成率とフェロプトーシスマーカーを分析した.
  • 救出効果を評価するためにフェロプトーシス阻害剤を使用した.
  • HSCフェロプトーシスに対するMYSM1過剰発現の効果を調査した.

主要な成果:

  • HSCにおけるタンパク質合成の減少はフェロプトーシスの増加と相関する.
  • タンパク質合成の速さに関係なく,フェロプトーシスを遮断すると,HSCの維持が完全に救われます.
  • このフェロプトーシスの脆弱性は,ヒトのHSCの特徴であり,MYSM1欠乏症の根底にある.
  • MYSM1過剰発現によるタンパク質合成の増加は,HSCのフェロプトーシスに対する感受性を低下させる.

結論:

  • HSCにおける生理学的適応は,調節されたタンパク質合成のように,特にフェロプトーシスに対する特定の脆弱性を生み出します.
  • フェロプトーシスをターゲットにすることで,骨髄機能不全の疾患におけるHSCの損失を救済する戦略が提供されます.
  • これらの脆弱性を理解することは,HSCの維持と体幹細胞生物学にとって極めて重要です.